Impact of a probiotic product on bowel habits and microbial profile in participants with functional constipation: A randomized controlled trial
Authors:
Open Access
- 4 July 2019
- journal article
- research article
- Published by Wiley in Journal of Digestive Diseases
- Vol. 20 (9) , 435-446
Abstract
Objective: To investigate the clinical efficacy of a multi‐strain probiotic product on bowel habits and microbial profile in participants with functional constipation.Methods: This was a randomized, double‐blind, placebo‐controlled and parallel‐arm study. Altogether 94 otherwise healthy adults aged 18 to 65 years with symptoms of functional constipation were randomized as part of the intention‐to‐treat population. The participants received a placebo or the probiotic product (1.5 × 1010 CFU/day), consisting of Lactobacillus acidophilus DDS‐1, Bifidobacterium animalis subsp. lactis UABla‐12, Bifidobacterium longum UABl‐14 and Bifidobacterium bifidum UABb‐10 over 4 weeks. Outcomes included the patient assessment of constipation‐symptom (PAC‐SYM) questionnaire, stool frequency and consistency, and microbial profile.Results: There were no significant between‐group differences in the PAC‐SYM score, despite significant within‐group differences (P < 0.001) over the study period. The probiotic group showed a faster normalization of stool frequency and consistency, with most participants achieving a normalized profile after 1 week. Fecal samples of the probiotic group exhibited higher relative abundance of Ruminococcaceae (P = 0.0047), including the Ruminococcus genus, and lower relative abundance of Erysipelotrichaceae (P = 0.0172) at end‐point compared with baseline. Placebo group samples showed similar abundance profiles over the study, with the exception of Clostridiaceae, which was lower at the study end‐point (P = 0.0033). Among treated participants, all four probiotic strains were significantly more abundant after the intervention.Conclusions: No significant differences were observed in symptomology, with both groups showing a more than 20% improvement. However, the probiotic helped modulate bowel function earlier than the placebo, with a corresponding shift to a more fibrolytic microbiota.Keywords
This publication has 56 references indexed in Scilit:
- Human Intestinal Lumen and Mucosa-Associated Microbiota in Patients with Colorectal CancerPLOS ONE, 2012
- An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaeaThe ISME Journal, 2011
- Linking Long-Term Dietary Patterns with Gut Microbial EnterotypesScience, 2011
- Intestinal Microbiota in Healthy Adults: Temporal Analysis Reveals Individual and Common Core and Relation to Intestinal SymptomsPLOS ONE, 2011
- Intestinal microbiota in human health and disease: the impact of probioticsGenes & Nutrition, 2011
- Global patterns of 16S rRNA diversity at a depth of millions of sequences per sampleProceedings of the National Academy of Sciences of the United States of America, 2010
- Gender differences in self-reported constipation characteristics, symptoms, and bowel and dietary habits among patients attending a specialty clinic for constipationGender Medicine, 2009
- Human gut microbiota in obesity and after gastric bypassProceedings of the National Academy of Sciences of the United States of America, 2009
- Gene-centric metagenomics of the fiber-adherent bovine rumen microbiome reveals forage specific glycoside hydrolasesProceedings of the National Academy of Sciences, 2009
- An Ordination of the Upland Forest Communities of Southern WisconsinEcological Monographs, 1957